Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on developing treatments for cancer. The company is known for its innovative therapies, including cabozantinib, which targets various types of cancer. Exelixis competes with other biotech firms like Amgen and Gilead Sciences in the oncology space.
On January 8, 2026, Robert Burns from H.C. Wainwright set a price target of $52 for Exelixis. At that time, the stock was trading at $44.79, suggesting a potential upside of 16.1%. This optimistic outlook aligns with Exelixis' recent strategic moves, including its collaboration with Natera for the phase III STELLAR-316 study.
The collaboration with Natera focuses on testing zanzalintinib in patients with resected stage II/III colorectal cancer. This study will evaluate the efficacy of Exelixis' novel oral kinase inhibitor, zanzalintinib, both with and without an immune checkpoint inhibitor, in patients who are MRD-positive. The trial's primary endpoint is disease-free survival, and it is expected to start in mid-2026.
Following the announcement of this collaboration, Exelixis' stock saw a 6% increase on January 7. Over the past year, Exelixis' shares have risen by 33.9%, significantly outperforming the industry's gain of 17.2%. This strong performance reflects investor confidence in the company's growth prospects and strategic initiatives.
Currently, Exelixis' stock price is approximately $44.74, showing a decrease of about 3.14% or $1.45. During the trading day, the stock fluctuated between a low of $44.39 and a high of $45.84. Over the past year, EXEL has reached a high of $49.62 and a low of $31.90. The company has a market capitalization of approximately $11.99 billion, with a trading volume of 561,415 shares.
